Novo's Prandin: Challenging Established Practice
Introducing Prandin, an entirely novel class of oral anti-diabetic drug that requires the adoption of a new treatment paradigm in type 2 diabetes was always going to be difficult for Novo Nordisk. While the new drug and treatment concept have not caught on in the US, Novo's strength in the European diabetes market has helped it win a bigger market share there and indeed outdo its much larger rival Novartis, with its drug Starlix.
You may also be interested in...
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.